Welcome to our dedicated page for Naturl Alt Intl news (Ticker: NAII), a resource for investors and traders seeking the latest updates and insights on Naturl Alt Intl stock.
Natural Alternatives International, Inc. reports developments in customized nutritional supplement manufacturing, proprietary ingredients, and customer supply relationships. The company formulates, manufactures, and markets nutritional supplements and provides strategic partnering services that include scientific research, product formulation, testing, packaging, regulatory review, and international product registration assistance.
Recurring announcements cover private-label contract manufacturing sales, quarterly results, manufacturing agreements, credit-facility updates, and the CarnoSyn® Brands portfolio. Product updates include CarnoSyn® beta-alanine, CarnoSyn® 4X, and TriBsyn® applications across sports performance, ready-to-drink beverages, protein drinks, dairy, and medical nutrition.
Natural Alternatives International (NAII) reported a strong fiscal Q4 2021, posting a net income of $3.0 million, or $0.47 per diluted share, on sales of $44.4 million, a 26.5% increase from the previous year. Annual net income for FY 2021 reached $10.8 million, with sales up 50.2% to $178.5 million. Private-label contract manufacturing sales rose by 54.6%, attributed to increased demand for immune products during the pandemic. Anticipating a 5-10% sales increase for FY 2022, NAII expects initial challenges in the first half due to supply chain issues, but positive growth is anticipated in the latter half.
Natural Alternatives International, Inc. (NAII) has acquired a 54,154 ft2 manufacturing and warehouse facility in Carlsbad, CA, for $17.5 million, with $10 million financed through a term loan and $7.5 million in cash. This facility will be retrofitted for high-volume powder blending and packaging, enhancing raw material storage capacity to support projected domestic sales growth. CEO Mark A. Le Doux emphasized the strategic importance of this investment, as it aims to improve production capabilities and expand customer service in the growing powder packaged delivery segment.
Natural Alternatives International, Inc. (NAII) has secured a new credit facility with Wells Fargo Bank, increasing its borrowing capacity from $10 million to $20 million. This facility will support ongoing working capital and potential future acquisitions, with a maturity date extended to May 24, 2024. CEO Mark A. Le Doux emphasized the importance of this facility in strengthening NAII's financial position, enabling the company to pursue growth opportunities. The enhanced financial capability reflects NAII's solid balance sheet and successful operations.
Natural Alternatives International (NAII) reported a net income of $1.9 million ($0.30 per diluted share) for Q3 FY2021, reversing a net loss of $4.0 million in Q3 FY2020. Net sales surged 81.8% to $46.3 million, boosted by a significant increase in private-label contract manufacturing sales, which grew 86.2%. For the nine months ending March 31, 2021, net income was $7.8 million compared to a loss of $3.4 million in the previous year. The company expects annualized FY2021 net sales to rise by 45% to 55%, while also maintaining strong cash reserves of $28.1 million.
Natural Alternatives International, Inc. (NAII) has announced a $3.0 million increase to its stock repurchase plan, raising the total authorization to $15.0 million. This plan allows for the repurchase of shares based on market conditions, with 1.6 million shares already acquired. After this increase, $3.2 million remains available for further repurchases. The company's stock buyback strategy aims to enhance shareholder value amid ongoing market dynamics.
Natural Alternatives International, Inc. (NAII) has released an investor presentation aimed at enhancing communication with current and potential shareholders. The presentation is part of a broader initiative to articulate the company's long-term direction and management goals. CEO Mark A. Le Doux highlighted the firm’s plans to engage more with institutional investors and participate in conferences, signaling optimism about upcoming opportunities in their pipeline. The presentation is accessible on their investor relations webpage.
Natural Alternatives International (NAII) reported a significant increase in net income to $3.6 million ($0.57/share) for Q2 FY2021, a notable rise from $0.5 million ($0.07/share) last year. Net sales reached $48.1 million, up 65.2% from $29.1 million. Private-label contract manufacturing soared by 82.5%, whereas CarnoSyn® sales dropped 35.5%, impacted by competition and COVID-19. Year-to-date income stands at $5.9 million ($0.91/share), with expectations of 30% to 50% sales growth for FY2021 and operating income between 5% and 7%. Cash as of December 31, 2020, was $28.6 million.
Natural Alternatives International, Inc. (NAII) announced the full repayment of its outstanding $10 million credit line with Wells Fargo Bank as of February 2, 2021. This credit line was initially secured during the early pandemic uncertainty in March 2020. CEO Mark A. Le Doux emphasized that the strong business environment and increased consumer demand for dietary supplements made this repayment feasible. The line of credit is now available again for future needs through November 2022, reflecting the company’s solid cash flow and financial health.
Natural Alternatives International, Inc. (NAII) reported a net income of $2.3 million, or $0.35 per diluted share, with net sales reaching $39.7 million for the first quarter of fiscal 2021, ending September 30, 2020. This reflects a 36.1% increase in sales compared to the previous year. The company attributed growth to increased private-label contract manufacturing, particularly in immune and wellness products amid the COVID-19 pandemic. However, royalty and licensing revenue from CarnoSyn® beta-alanine declined 15.9%. NAII expects annual sales to rise 30% to 50% in fiscal 2021.
Natural Alternatives International, Inc. (NAII) reported a 16% increase in consolidated net sales for Q4 2020, reaching $35.1 million. However, FY 2020 sales declined 14% to $118.9 million. The company posted a Q4 net income of $1.8 million compared to a loss of $0.02 million in Q4 2019. Net loss for FY 2020 was $1.6 million due to a $4.3 million reserve related to a former customer. A stock repurchase plan was increased by $2 million, totaling $12 million. The outlook for FY 2021 is positive, with expected sales growth.